Treatment of Akathisia
First-line treatment for antipsychotic-induced akathisia is reducing the antipsychotic dose while maintaining therapeutic efficacy, followed by propranolol 10-30 mg two to three times daily if dose reduction is insufficient. 1
Stepwise Treatment Algorithm
Step 1: Antipsychotic Adjustment
- Reduce the current antipsychotic dose to decrease dopamine D2 receptor blockade, which is the root cause of akathisia 1
- If dose reduction is insufficient or not feasible, switch to quetiapine or olanzapine, which have significantly lower akathisia liability compared to high-potency agents like haloperidol 1
- Even clozapine, quetiapine, aripiprazole and cariprazine—which induce minimal other extrapyramidal side effects—may still cause akathisia 2
Step 2: Pharmacological Treatment When Antipsychotic Adjustment Fails
Most Effective Options (in order of evidence strength):
- Mirtazapine 15 mg/day is the most effective treatment based on the highest quality evidence, with the best efficacy and tolerability profile 3, 4, 5
- Propranolol 10-30 mg two to three times daily is the most consistently effective traditional pharmacological treatment 1, 6
- Vitamin B6 600-1200 mg/day shows strong efficacy with excellent tolerability 3
- Biperiden 6 mg/day demonstrates robust efficacy for at least 14 days 3
Alternative Effective Options:
- Trazodone 50 mg/day 3
- Mianserin 15 mg/day 3
- Clonazepam (benzodiazepines) 6, 7
- Anticholinergics 7
- Gabapentin or pregabalin 2, 6
Ineffective Options to Avoid:
- Cyproheptadine, clonazepam, zolmitriptan, and valproate did not yield significant effects in network meta-analysis 3
Critical Clinical Pitfalls
The most dangerous mistake: Akathisia is frequently misinterpreted as psychotic agitation or anxiety, leading clinicians to inappropriately increase antipsychotic doses, which paradoxically worsens the condition 1
Essential monitoring: Systematically assess patients with validated scales such as the Barnes Akathisia Rating Scale before starting antipsychotics and during dose titration to catch akathisia early 1, 7
SSRI-induced akathisia warning: SSRI-induced akathisia, particularly with fluoxetine, is associated with increased suicidality—systematically inquire about suicidal ideation before and after treatment initiation 1
High-Risk Populations Requiring Vigilance
- Children and adolescents have higher risk for extrapyramidal side effects including akathisia compared to adults 1
- Young age and male gender are additional risk factors for acute extrapyramidal reactions 1
- Prophylactic antiparkinsonian agents may be considered in high-risk patients such as those with history of dystonic reactions, young males, or paranoid patients with compliance concerns 1
Duration and Reassessment
- Reevaluate the need for adjunctive agents after the acute phase, as many patients no longer require them during long-term therapy once antipsychotic doses are stabilized 1
- Chronic and tardive akathisia may persist after the causative agent is withdrawn and prove resistant to pharmacological treatment 2
- Rotation between different pharmacological management strategies may be optimal in resistant cases 2